Pancreatic Cancer Research

ResearcherTianjin Medical University Cancer Institute and HospitalActive in the last 2 years

Weidong Ma

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5160379162. Sources: OpenAlex.

Their work

Papers
9 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: 2 papers · 2024: none · 2025: none · 2026: 1 paper

Papers 9

  1. Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 tri… Co-author DOI 10.1038/s41392-026-02966-0↗
  2. Systemic Chemotherapy With or Without Hepatic Arterial Infusion Chemotherapy for Liver Metastases From Pancreatic Cancer: A Propensity Score Matching Analysis. First author DOI 10.1016/j.clcc.2022.10.007↗
  3. Is lung involvement a favorable prognostic factor for pancreatic ductal adenocarcinoma with synchronous liver metastases?-A propensity score analysis. First author DOI 10.1080/17474124.2023.2183497↗
  4. MicroRNA-608 promotes apoptosis via BRD4 downregulation in pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2019.11246↗
  5. LOX and ACSL5 as potential relapse markers for pancreatic cancer patients. Co-author DOI 10.1080/15384047.2018.1564565↗
  6. Systemic chemotherapy in combination with liver-directed therapy improves survival in patients with pancreatic adenocarcinoma and synchronous liver metastases. First author DOI 10.1016/j.pan.2018.09.015↗
  7. Factors influencing survival of patients with pancreatic adenocarcinoma and synchronous liver metastases receiving palliative care. First author DOI 10.1016/j.pan.2017.07.002↗
  8. Single nucleotide polymorphism in the microRNA-199a binding site of HIF1A gene is associated with pancreatic ductal adenocarcinoma risk and worse clinical outc… Co-author DOI 10.18632/oncotarget.7263↗
  9. Improvement in treatment and outcome of pancreatic ductal adenocarcinoma in north China. Co-author DOI 10.1007/s11605-011-1493-y↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Huaqiang Ouyang · 4 shared papers, 2017–2023 · strength 0.56
  2. Xiuchao Wang · 4 shared papers, 2016–2026 · strength 0.51
  3. Anna Sandström Gerdtsson · 2 shared papers, 2023 · strength 0.40
  4. Donglin Liu · 2 shared papers, 2023 · strength 0.40
  5. Zhanyu Pan · 3 shared papers, 2017–2023 · strength 0.38
  6. Tiansuo Zhao · 2 shared papers, 2016–2026 · strength 0.25
  7. Chuntao Gao · 1 shared paper, 2026 · strength 0.20
  8. Jihui Hao · 1 shared paper, 2026 · strength 0.20
  9. Jun Yu · 1 shared paper, 2026 · strength 0.20
  10. Yongjie Xie · 1 shared paper, 2026 · strength 0.20
  11. Qingxiao Fang · 1 shared paper, 2026 · strength 0.20
  12. Yukuan Feng · 1 shared paper, 2026 · strength 0.20
  13. Shangheng Shi · 1 shared paper, 2026 · strength 0.20
  14. Chao Yang · 1 shared paper, 2026 · strength 0.20
  15. Zhuchen Yan · 1 shared paper, 2023 · strength 0.18
  16. Ping Chen · 1 shared paper, 2023 · strength 0.18
  17. Tongguo Si · 1 shared paper, 2023 · strength 0.18
  18. Manman Quan · 2 shared papers, 2017–2018 · strength 0.16
  19. Maoyuan Li · 1 shared paper, 2020 · strength 0.15
  20. Gang Zhao · 1 shared paper, 2020 · strength 0.15
  21. Ting Li · 1 shared paper, 2020 · strength 0.15
  22. Hui Li · 1 shared paper, 2019 · strength 0.11
  23. Ting Li · 1 shared paper, 2019 · strength 0.11
  24. Shengyu Yang · 1 shared paper, 2016 · strength 0.06
  25. Jihui Hao · 1 shared paper, 2016 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.